منابع مشابه
The elusive disconnection between mortality and early stent thrombosis: observations from the CHAMPION-PHOENIX trial.
doi:10.1160/TH13-10-0846 Thromb Haemost 2014; 111: 8–9 Ever since coronary stenting became the standard of care for the treatment of acute ST-elevation myocardial (STEMI), the flip side of this approach became evident. Stent thrombosis annihilates the effect of early and complete reperfusion of the culprit lesion, and leads to considerable mortality (1). Failure to inhibit platelets contributes...
متن کاملDisbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
The recently published, largest trial with cangrelor, the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PHOENIX, suggested that the experimental agent significantly reduced the rate of stent thrombosis (ST) and myocardial infarction (MI) during PCI at 48 hours (h) and 30 days. However, the declared impressive cangrelor vascular non-fatal benef...
متن کاملThe effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
AIMS To assess whether the use of the femoral or radial approach for percutaneous coronary intervention (PCI) interacted with the efficacy and safety of cangrelor, an intravenous P2Y12 inhibitor, in CHAMPION PHOENIX. METHODS AND RESULTS A total of 11 145 patients were randomly assigned in a double-dummy, double-blind manner either to a cangrelor bolus and 2-h infusion or to clopidogrel at the...
متن کاملCangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX.
BACKGROUND Older patients treated with percutaneous coronary intervention are at increased risk of periprocedural events. METHODS AND RESULTS CHAMPION (cangrelor versus standard therapy to achieve optimal management of platelet inhibition) PHOENIX randomized 11 145 patients to cangrelor or clopidogrel. We sought to determine the outcomes in the prespecified subgroup of patients ≥75 years old ...
متن کاملVariation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
BACKGROUND The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients undergoing percutaneous coronary intervention compared with clopidogrel. METHODS AND RESULTS We analyzed all patients included in the modified intention-to-treat analysis in US (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Heart Journal
سال: 2013
ISSN: 0019-4832
DOI: 10.1016/j.ihj.2013.08.005